Adrian Rawcliffe

Insider · Director · WVE

Adrian Rawcliffe files insider transactions with the SEC as a director of Wave Life Sciences (WVE). We hold 1 disclosed purchase or sale filed since 20 January 2016, 1 of them in the last 90 days.

Files forWVE
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure13 August 2026

Positions held

3 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 1 February 2017 — 12 August 2026Director · Wave Life Sciences (WVE)17 Form 4 lines · source: SEC Form 4
Filed 18 January 2016 — 20 February 2025Chief Executive Officer · Adaptimmune Therapeutics (ADAP)52 Form 4 lines · source: SEC Form 4
Filed 1 September 2021 — 1 September 2021Chief Executive Officer · Adaptimmune Therapeutics (ADAP])1 Form 4 line · source: SEC Form 4

Everything they disclosed

70 entries, newest first — one per disclosure report, one per Form 4 line

▼ sold on the open market 12,700 shares of Wave Life SciencesSEC Form 413 August 2026Common Stock · traded 12 August 2026 · filed 13 August 2026
exercised options over 42,000 shares of Wave Life Sciences (a derivative holding)SEC Form 410 December 2025Share Option (right to buy) · traded 8 December 2025 · filed 10 December 2025
exercised options over 42,000 shares of Wave Life SciencesSEC Form 410 December 2025Ordinary Shares · traded 8 December 2025 · filed 10 December 2025
▼ sold on the open market 42,000 shares of Wave Life SciencesSEC Form 410 December 2025Ordinary Shares · traded 8 December 2025 · filed 10 December 2025
▼ sold on the open market 16,115 shares of Wave Life SciencesSEC Form 414 November 2025Ordinary Shares · traded 13 November 2025 · filed 14 November 2025
was granted 76,200 shares of Wave Life Sciences (a derivative holding)SEC Form 413 August 2025Share Option (right to buy) · traded 11 August 2025 · filed 13 August 2025
was granted 12,700 shares of Wave Life SciencesSEC Form 413 August 2025Ordinary Shares · traded 11 August 2025 · filed 13 August 2025
was granted 5,143,248 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 420 February 2025Option to purchase Ordinary Shares · traded 20 February 2025 · filed 20 February 2025
was granted 3,428,832 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 420 February 2025Option to purchase Ordinary Shares · traded 20 February 2025 · filed 20 February 2025
▼ sold on the open market 30,601 shares of Adaptimmune TherapeuticsSEC Form 417 January 2025American Depositary Shares representing Ordinary Shares · traded 17 January 2025 · filed 17 January 2025
▼ sold on the open market 12,539 shares of Adaptimmune TherapeuticsSEC Form 415 January 2025American Depositary Shares representing Ordinary Shares · traded 13 January 2025 · filed 15 January 2025
▼ sold on the open market 17,934 shares of Adaptimmune TherapeuticsSEC Form 415 January 2025American Depositary Shares representing Ordinary Shares · traded 13 January 2025 · filed 15 January 2025
▼ sold on the open market 29,096 shares of Adaptimmune TherapeuticsSEC Form 415 January 2025American Depositary Shares representing Ordinary Shares · traded 15 January 2025 · filed 15 January 2025
was granted 32,230 shares of Wave Life Sciences (a derivative holding)SEC Form 414 August 2024Share Option (right to buy) · traded 12 August 2024 · filed 14 August 2024
was granted 16,115 shares of Wave Life SciencesSEC Form 414 August 2024Ordinary Shares · traded 12 August 2024 · filed 14 August 2024
was granted 7,633,296 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2024Option to purchase Ordinary Shares · traded 15 January 2024 · filed 17 January 2024
was granted 1,696,272 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2024Option to purchase Ordinary Shares · traded 15 January 2024 · filed 17 January 2024
▼ sold on the open market 9,304 shares of Adaptimmune TherapeuticsSEC Form 417 January 2024American Depositary Shares representing Ordinary Shares · traded 16 January 2024 · filed 17 January 2024
▼ sold on the open market 30,080 shares of Adaptimmune TherapeuticsSEC Form 417 January 2024American Depositary Shares representing Ordinary Shares · traded 17 January 2024 · filed 17 January 2024
▼ sold on the open market 11,945 shares of Adaptimmune TherapeuticsSEC Form 412 January 2024American Depositary Shares representing Ordinary Shares · traded 11 January 2024 · filed 12 January 2024
▼ sold on the open market 17,257 shares of Adaptimmune TherapeuticsSEC Form 412 January 2024American Depositary Shares representing Ordinary Shares · traded 12 January 2024 · filed 12 January 2024
▼ sold on the open market 2,403 shares of Adaptimmune TherapeuticsSEC Form 41 September 2023American Depositary Shares representing Ordinary Shares · traded 1 September 2023 · filed 1 September 2023
was granted 45,000 shares of Wave Life Sciences (a derivative holding)SEC Form 49 August 2023Share Option (right to buy) · traded 7 August 2023 · filed 9 August 2023
▼ sold on the open market 2,333 shares of Adaptimmune TherapeuticsSEC Form 427 June 2023American Depositary Shares representing Ordinary Shares · traded 27 June 2023 · filed 27 June 2023
was granted 4,690,224 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2023Option to purchase Ordinary Shares · traded 17 January 2023 · filed 17 January 2023
was granted 1,798,272 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2023Option to purchase Ordinary Shares · traded 17 January 2023 · filed 17 January 2023
▼ sold on the open market 10,057 shares of Adaptimmune TherapeuticsSEC Form 417 January 2023American Depositary Shares representing Ordinary Shares · traded 17 January 2023 · filed 17 January 2023
▼ sold on the open market 13,042 shares of Adaptimmune TherapeuticsSEC Form 412 January 2023American Depositary Shares representing Ordinary Shares · traded 11 January 2023 · filed 12 January 2023
▼ sold on the open market 18,763 shares of Adaptimmune TherapeuticsSEC Form 412 January 2023American Depositary Shares representing Ordinary Shares · traded 12 January 2023 · filed 12 January 2023
▼ sold on the open market 5,073 shares of Adaptimmune TherapeuticsSEC Form 44 January 2023American Depositary Shares representing Ordinary Shares · traded 4 January 2023 · filed 4 January 2023
▼ sold on the open market 2,536 shares of Adaptimmune TherapeuticsSEC Form 41 September 2022American Depositary Shares representing Ordinary Shares · traded 1 September 2022 · filed 1 September 2022
was granted 21,000 shares of Wave Life Sciences (a derivative holding)SEC Form 417 August 2022Share Option (right to buy) · traded 15 August 2022 · filed 17 August 2022
▼ sold on the open market 2,562 shares of Adaptimmune TherapeuticsSEC Form 427 June 2022American Depositary Shares representing Ordinary Shares · traded 27 June 2022 · filed 27 June 2022
▼ sold on the open market 11,096 shares of Adaptimmune TherapeuticsSEC Form 418 January 2022American Depositary Shares representing Ordinary Shares · traded 18 January 2022 · filed 18 January 2022
was granted 4,690,224 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 413 January 2022Option to purchase Ordinary Shares · traded 12 January 2022 · filed 13 January 2022
was granted 1,047,480 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 413 January 2022Option to purchase Ordinary Shares · traded 12 January 2022 · filed 13 January 2022
▼ sold on the open market 14,362 shares of Adaptimmune TherapeuticsSEC Form 413 January 2022American Depositary Shares representing Ordinary Shares · traded 11 January 2022 · filed 13 January 2022
▼ sold on the open market 3,046 shares of Adaptimmune TherapeuticsSEC Form 413 January 2022American Depositary Shares representing Ordinary Shares · traded 12 January 2022 · filed 13 January 2022
▼ sold on the open market 5,532 shares of Adaptimmune TherapeuticsSEC Form 45 January 2022American Depositary Shares representing Ordinary Shares · traded 4 January 2022 · filed 5 January 2022
▼ sold on the open market 2,782 shares of Adaptimmune TherapeuticsSEC Form 41 September 2021American Depositary Shares representing Ordinary Shares · traded 1 September 2021 · filed 1 September 2021
was granted 42,000 shares of Wave Life Sciences (a derivative holding)SEC Form 418 August 2021Share Option (right to buy) · traded 16 August 2021 · filed 18 August 2021
▼ sold on the open market 2,794 shares of Adaptimmune TherapeuticsSEC Form 428 June 2021American Depositary Shares representing Ordinary Shares · traded 28 June 2021 · filed 28 June 2021
▼ sold on the open market 9,879 shares of Adaptimmune TherapeuticsSEC Form 419 January 2021American Depositary Shares representing Ordinary Shares · traded 19 January 2021 · filed 19 January 2021
▼ sold on the open market 2,707 shares of Adaptimmune TherapeuticsSEC Form 412 January 2021American Depositary Shares representing Ordinary Shares · traded 12 January 2021 · filed 12 January 2021
was granted 3,260,400 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 411 January 2021Option to purchase Ordinary Shares · traded 11 January 2021 · filed 11 January 2021
was granted 728,160 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 411 January 2021Option to purchase Ordinary Shares · traded 11 January 2021 · filed 11 January 2021
▼ sold on the open market 4,967 shares of Adaptimmune TherapeuticsSEC Form 45 January 2021American Depositary Shares representing Ordinary Shares · traded 4 January 2021 · filed 5 January 2021
▼ sold on the open market 2,776 shares of Adaptimmune TherapeuticsSEC Form 42 September 2020American Depositary Shares representing Ordinary Shares · traded 1 September 2020 · filed 2 September 2020
was granted 10,500 shares of Wave Life Sciences (a derivative holding)SEC Form 420 August 2020Share Option (right to buy) · traded 18 August 2020 · filed 20 August 2020
▼ sold on the open market 2,788 shares of Adaptimmune TherapeuticsSEC Form 44 August 2020American Depositary Shares representing Ordinary Shares · traded 3 August 2020 · filed 4 August 2020
was granted 2,515,536 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2020Option to purchase Ordinary Shares · traded 16 January 2020 · filed 17 January 2020
was granted 561,792 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2020Option to purchase Ordinary Shares · traded 16 January 2020 · filed 17 January 2020
▼ sold on the open market 3,236 shares of Adaptimmune TherapeuticsSEC Form 415 January 2020American Depositary Shares representing Ordinary Shares · traded 14 January 2020 · filed 15 January 2020
▼ sold on the open market 5,900 shares of Adaptimmune TherapeuticsSEC Form 47 January 2020American Depositary Shares representing Ordinary Shares · traded 6 January 2020 · filed 7 January 2020
was granted 628,872 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 43 September 2019Option to purchase Ordinary Shares · traded 1 September 2019 · filed 3 September 2019
was granted 140,448 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 43 September 2019Option to purchase Ordinary Shares · traded 1 September 2019 · filed 3 September 2019
was granted 10,500 shares of Wave Life Sciences (a derivative holding)SEC Form 416 August 2019Share Option (right to buy) · traded 15 August 2019 · filed 16 August 2019
was granted 628,872 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 427 June 2019Option to purchase Ordinary Shares · traded 27 June 2019 · filed 27 June 2019
was granted 140,448 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 427 June 2019Option to purchase Ordinary Shares · traded 27 June 2019 · filed 27 June 2019
▼ sold on the open market 3,084 shares of Adaptimmune TherapeuticsSEC Form 416 January 2019American Depositary Shares representing Ordinary Shares · traded 14 January 2019 · filed 16 January 2019
was granted 1,257,744 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 48 January 2019Option to purchase Ordinary Shares · traded 4 January 2019 · filed 8 January 2019
was granted 280,896 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 48 January 2019Option to purchase Ordinary Shares · traded 4 January 2019 · filed 8 January 2019
was granted 9,000 shares of Wave Life Sciences (a derivative holding)SEC Form 415 August 2018Share Option (right to buy) · traded 13 August 2018 · filed 15 August 2018
▼ sold on the open market 600,000 shares of Adaptimmune TherapeuticsSEC Form 422 March 2018Ordinary Shares · traded 20 March 2018 · filed 22 March 2018
was granted 687,984 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2018Option to purchase Ordinary Shares · traded 12 January 2018 · filed 17 January 2018
was granted 153,648 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 417 January 2018Option to purchase Ordinary Shares · traded 12 January 2018 · filed 17 January 2018
was granted 9,000 shares of Wave Life Sciences (a derivative holding)SEC Form 417 August 2017Share Option (right to buy) · traded 10 August 2017 · filed 17 August 2017
was granted 18,000 shares of Wave Life Sciences (a derivative holding)SEC Form 41 February 2017Share Option (right to buy) · traded 1 February 2017 · filed 1 February 2017
was granted 2,072,976 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 418 January 2017Option to purchase Ordinary Shares · traded 13 January 2017 · filed 18 January 2017
was granted 939,948 shares of Adaptimmune Therapeutics (a derivative holding)SEC Form 420 January 2016Option to purchase Ordinary Shares · traded 18 January 2016 · filed 20 January 2016

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.